Cite
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer.
MLA
Kostecki, Kourtney L., et al. “Dual Axl/MerTK Inhibitor INCB081776 Creates a Proinflammatory Tumor Immune Microenvironment and Enhances Anti‐PDL1 Efficacy in Head and Neck Cancer.” Head & Neck, vol. 45, no. 5, May 2023, pp. 1255–71. EBSCOhost, https://doi.org/10.1002/hed.27340.
APA
Kostecki, K. L., Iida, M., Wiley, A. L., Kimani, S., Mehall, B., Tetreault, K., Alexandridis, R., Yu, M., Hong, S., Salgia, R., Bruce, J. Y., Birge, R. B., Harari, P. M., & Wheeler, D. L. (2023). Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer. Head & Neck, 45(5), 1255–1271. https://doi.org/10.1002/hed.27340
Chicago
Kostecki, Kourtney L., Mari Iida, Anne L. Wiley, Stanley Kimani, Bridget Mehall, Kaitlin Tetreault, Roxana Alexandridis, et al. 2023. “Dual Axl/MerTK Inhibitor INCB081776 Creates a Proinflammatory Tumor Immune Microenvironment and Enhances Anti‐PDL1 Efficacy in Head and Neck Cancer.” Head & Neck 45 (5): 1255–71. doi:10.1002/hed.27340.